48 results on '"Kukreti, Vishal"'
Search Results
2. The Impact of CD34+ Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma
3. Very late relapse in Hodgkin lymphoma: Characterizing an understudied population
4. A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
5. Post Salvage Therapy Autologous Transplant for Relapsed Myeloma, Ongoing Relevance within Modern Treatment Paradigms?
6. Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre‐autologous stem cell transplant in relapsed/refractory diffuse large B‐cell lymphoma—outcome of rituximab‐dose‐intensive cyclophosphamide, etoposide, cisplatin (R‐DICEP) versus R‐GDP
7. Predicting the Risks of Aggressive-Intent Chemotherapy Toxicity in Older Patients With Lymphoma: A Prospective Observational Pilot Study
8. Light Chain Amyloidosis (AL) Associated With B Cell Lymphoma a Single Center Experience
9. Implementation and Impact of Choosing Wisely Recommendations in Oncology
10. Implementation of medication reconciliation in outpatient cancer care
11. The Impact of CD34+ Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma.
12. Impact of a Training Program on Oncology Nurses’ Confidence in the Provision of Self-Management Support and 5As Behavioral Counseling Skills
13. Feasibility and Effectiveness of Self-Management Education and Coaching on Patient Activation for Managing Cancer Treatment Toxicities
14. The I-Can Manage web-based cancer self-management program targeting treatment toxicities and health behaviours: Human centred co-design approach and cognitive-think aloud usability testing (Preprint)
15. Human centered co-design and usability testing of a web-based cancer self-management education program (I-Can Manage) targeting treatment toxicities and health behaviours (Preprint)
16. Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma
17. Clinical Characteristics and Disease Outcomes in Primary Bone Lymphoma: Retrospective Study
18. Frailty in Patients Undergoing Chimeric Antigen Receptor T-Cell (CAR T) Therapy at Princess Margaret Cancer Centre: A Prospective Pilot Study
19. Correlation Amongst Scoring of Various Frailty Tools in Myeloma Patients Undergoing Autologous Stem Cell Transplantation
20. Crebbp Mutations Are Associated with Shorter Time to Progression in Limited-Stage Follicular Lymphoma Treated with Radiation
21. From Choosing Wisely to Implementing Wisely in Cancer Care: A Scoping Review
22. Clinical utility of interim CT scans in patients receiving chemoimmuntherapy for first line treatment of follicular lymphoma
23. Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma
24. High Risk of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated With First-Line Bendamustine Rituximab and Rituximab Maintenance
25. IBCL-550 High Risk of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated With First-line Bendamustine Rituximab and Rituximab Maintenance
26. Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume
27. Kinetics of response to first‐ and second‐line therapies in multiple myeloma: Assessment by both M‐spikes and light chains
28. Outcomes in Relapsed/Refractory Burkitt Lymphoma: A Multi-Centre Canadian Experience
29. Risk Stratification for Relapsed/Refractory Classical Hodgkin Lymphoma Integrating Pretransplant Deauville Score and Residual Metabolic Tumor Volume
30. Myeloma Patients with Deletion of 17p: Impact of Tandem Transplant and Clone Size
31. Clinical Significance of Clonal Hematopoiesis in the Setting of Autologous Stem Cell Transplantation for Lymphoma
32. Supermobilizers with High CD34 + Cell Collection for Autologous Transplant and Impact on Survival Outcomes in Multiple Myeloma
33. Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation
34. Recovery of a quality improvement project during the COVID pandemic.
35. Implementation and impact of Choosing Wisely recommendations in oncology: A scoping review.
36. Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis
37. Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis.
38. Kinetics of response to first‐ and second‐line therapies in multiple myeloma: Assessment by both M‐spikes and light chains.
39. Light Chain Amyloidosis (AL) Associated With B Cell Lymphoma a Single Center Experience.
40. A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
41. Selected Frailty Testing Can Predict for Risk of Febrile Neutropenia in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant
42. Considering Older Patients As Candidates for Auto Stem Cell Transplants: A Comprehensive Study on Toxicities and Survival Analysis
43. Neurocognitive Outcomes over the First 3 Months after Chimeric Antigen Receptor T-Cell (CAR T) Therapy: Preliminary Findings from a Longitudinal Study
44. Management and Outcomes for Primary Mediastinal B-Cell Lymphoma Patients with Partial Metabolic Response
45. Characterization of Clonal Hematopoietic of Indeterminate Potential (CHIP) Mutations in an Imid-Naïve Multiple Myeloma (MM) Autologous Stem Cell Transplant (ASCT) Population: First Results from a Pre-Transplant Time Point in a Prospective, Longitudinal Study
46. CrebbpMutations Are Associated with Shorter Time to Progression in Limited-Stage Follicular Lymphoma Treated with Radiation
47. Supermobilizers with High CD34 +Cell Collection for Autologous Transplant and Impact on Survival Outcomes in Multiple Myeloma
48. A Web-Based Cancer Self-Management Program (I-Can Manage) Targeting Treatment Toxicities and Health Behaviors: Human-Centered Co-design Approach and Cognitive Think-Aloud Usability Testing.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.